Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 12;229(4):1010-1018.
doi: 10.1093/infdis/jiad351.

Vaccine Take of RV3-BB Rotavirus Vaccine Observed in Indonesian Infants Regardless of HBGA Status

Celeste M Donato  1   2   3 , Amanda Handley  1   4 , Sean G Byars  5 , Nada Bogdanovic-Sakran  1 , Eleanor A Lyons  1 , Emma Watts  1 , Darren S Ong  1 , Daniel Pavlic  1 , Jarir At Thobari  6   7 , Cahya Dewi Satria  8 , Hera Nirwati  7   9 , Yati Soenarto  7   10 , Julie E Bines  1   2   11
Affiliations

Vaccine Take of RV3-BB Rotavirus Vaccine Observed in Indonesian Infants Regardless of HBGA Status

Celeste M Donato et al. J Infect Dis. .

Abstract

Background: Histo-blood group antigen (HBGA) status may affect vaccine efficacy due to rotavirus strains binding to HBGAs in a P genotype-dependent manner. This study aimed to determine if HBGA status affected vaccine take of the G3P[6] neonatal vaccine RV3-BB.

Methods: DNA was extracted from stool samples collected in a subset (n = 164) of the RV3-BB phase IIb trial in Indonesian infants. FUT2 and FUT3 genes were amplified and sequenced, with any single-nucleotide polymorphisms analyzed to infer Lewis and secretor status. Measures of positive cumulative vaccine take were defined as serum immune response (immunoglobulin A or serum-neutralizing antibody) and/or stool excretion of RV3-BB virus. Participants were stratified by HBGA status and measures of vaccine take.

Results: In 147 of 164 participants, Lewis and secretor phenotype were determined. Positive vaccine take was recorded for 144 (97.9%) of 147 participants with the combined phenotype determined. Cumulative vaccine take was not significantly associated with secretor status (relative risk, 1.00 [95% CI, .94-1.06]; P = .97) or Lewis phenotype (relative risk, 1.03 [95% CI, .94-1.14]; P = .33), nor was a difference observed when analyzed by each component of vaccine take.

Conclusions: The RV3-BB vaccine produced positive cumulative vaccine take, irrespective of HBGA status in Indonesian infants.

Keywords: Indonesia; histo-blood group antigen; neonatal vaccination; rotavirus; vaccine take.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. Murdoch Children's Research Institute holds the license for the RV3-BB vaccine. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
Participants through the study selection process and summary of stool specimen analysis to determine FUT2 and FUT3 genotype and inferred phenotype. Participant genotype was successfully determined for FUT2 (157/164) and FUT3 (149/164) with the combined FUT2 and FUT3 genotypes determined and phenotype inferred (147/164). Participants were excluded from analysis if the FUT2 or FUT3 amplification failed (AMP fail) or the resulting sequencing was of poor quality and not all single-nucleotide polymorphisms could be resolved (SNP fail).
See this image and copyright information in PMC

References

    1. Troeger C, Khalil IA, Rao PC, et al. Rotavirus vaccination and the global burden of rotavirus diarrhea among children younger than 5 years. JAMA Pediatr 2018; 172:958–65. - PMC - PubMed
    1. Cunliffe NA, Witte D, Ngwira BM, et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine 2012; 30(suppl 1):A36–43. - PMC - PubMed
    1. Madhi SA, Kirsten M, Louw C, et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial. Vaccine 2012; 30(suppl 1):A44–51. - PubMed
    1. Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376:615–23. - PubMed
    1. Marionneau S, Cailleau-Thomas A, Rocher J, et al. ABH and Lewis histo-blood group antigens, a model for the meaning of oligosaccharide diversity in the face of a changing world. Biochimie 2001; 83:565–73. - PubMed

Publication types